MBX Biosciences, Inc. Common Stock (MBX) is a publicly traded Healthcare sector company. As of May 20, 2026, MBX trades at $31.45 with a market cap of $1.47B and a P/E ratio of -13.25. MBX moved +3.31% today. Year to date, MBX is +7.23%; over the trailing twelve months it is +154.29%. Its 52-week range spans $4.81 to $45.85. Analyst consensus is strong buy with an average price target of $73.11. Rallies surfaces MBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MBX Biosciences Phase 1 Data Shows 7% Weight Loss, Monthly Dosing Potential: MBX Biosciences reported preliminary Phase 1 MAD Part B data for MBX 4291 showing mean 7% weight loss at week 8 with minimal GI events in an eight-participant cohort, supporting once-monthly dosing potential. It also nominated MBX 5765 as a once-monthly GLP-1/GIP/glucagon/DACRA candidate and cut imapextide Phase 2b funding.
| Metric | Value |
|---|---|
| Price | $31.45 |
| Market Cap | $1.47B |
| P/E Ratio | -13.25 |
| EPS | $-2.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.85 |
| 52-Week Low | $4.81 |
| Volume | 757.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-86.97M |
| Gross Margin | 0.00% |
10 analysts cover MBX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $73.11.